diagnost tool
biomed devic servic
diagnost tool
price close busi juli
acog may shift posit average-
risk nipt rais pt lh
increasingli posit stock attract non-invas prenat test
nipt market peg penetr women average-risk
birth typic women age last week american colleg obstetrician
 gynecologist acog withdrew practic bulletin doubt util nipt
average-risk women left acog practic bulletin
support check coupl nipt compani express optim
retir may lead newer bulletin support average-
risk nipt earli next month see new bulletin august fall
think larg commerci payor aet could follow acog endors issu
posit coverag decis average-risk nipt major catalyst present
model posit endors acog aet average-risk birth
thu posit develop would addit estim lh
rais pt street-high rais pt lh
also updat nipt market model figur
acog rather skeptic bulletin withdrawn last week acog withdrew
practic bulletin written septemb issu cautiou view
average-risk nipt given perform convent screen method
limit cell-fre dna screen perform limit data cost-
effect low-risk obstetr popul convent screen method
remain appropri choic first-lin screen women
gener obstetr popul bulletin indic patient
counsel cell-fre dna screen replac precis obtain
diagnost test chorion villu sampl amnio-centesi
therefor limit abil identifi chromosom abnorm
acog support bulletin remain acog bulletin
may remain indic sensit specif gener obstetr
popul similar level previous publish high-risk popul
women offer option aneuploidi screen diagnost test
fetal genet disord regardless matern age addit bulletin indic
one screen test superior test characterist howev cell-fre
dna screen offer highest report detect rate syndrom
peg us anoth grab estim us nipt
market penetr average-risk births/year
us penetr thu billion rev per year grab see figur
nipt market model estim live cover average-risk
women expect aet issu posit coverag decis earli
think drive double-digit growth nipt player
market leader double-digit growth feasibl player
drove nipt rev alon model
exclud chang average-risk nipt coverag decis estim
lh sequenom second-plac player revenu
player includ verinata roch ariosa progen counsyl
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
acog may shift posit averag risk
nipt reiter buy rate lh
rais pt street-high lh
increasingli posit stock exposur rapidly-grow non-
invas prenat test nipt market peg penetr
nipt women average-risk birth typic women age last week
american colleg obstetrician gynecologist acog withdrew practic bulletin
doubt util nipt average-risk women left
acog practic bulletin support recent check
coupl nipt compani express optim retir may
lead newer bulletin support average-risk nipt earli next month
see new bulletin august fall think larg commerci payor
aet could follow acog endors issu posit coverag decis
average-risk nipt major catalyst
present model posit endors acog aet
average-risk birth thu posit develop would addit
estim lh peg biggest winner market leader
follow lh even nasdaq
 rate look close acquisit counsyl inc rais
pt street-high rais pt lh
also updat nipt market model figur includ estim
nipt industri us market share estim top eight player
industri updat estim peg nearli
billion one favorit small-cap pick
figur canaccord genuiti nipt market model estim us nipt market penetr market penetr
average-risk nipt player also size total address market opportun nearli billion
diagnost tool
count catalyst track ahead updat announc
new partnership call possibl updat bulletin acog support
average-risk prenat test possibl coverag decis contract aet
and/or average-risk nipt convert test denial payment
estim could add rev test alreadi perform get
paid zero cog reduct work toward target low
cross-sel primarili cross-sel horizon
panorama also test uptak new test launch vistara
evercord other new pharma deal signatera cancer liquid biopsi
launch liquid biopsi cancer patient expect ldt
launch blood-bas kidney test possibl addit data set
organ ie heart read-out first result smart trial
end think help significantli increas
rate obtain reimburs microdelet test
today get paid time microdelet test
compar time average-risk nipt time high-risk
nipt total get paid approxim time overal
manag recent indic investor meet hope achiev
reimburs time within next year help average-risk
nipt like first follow improv microdelet test second
multipl sourc conservat street revenu estim keep
us posit stock out-year revenu estim exclud
revenu partnership decentr nipt test onto
generead sequenc expect begin contribut
increment revenu uptak average-risk nipt chang
acog expect coverag decis aet think
benefit model perhap revenu organ transplant reject
initi kidney test expect revenu acceler
microdelet test expect acceler upon enrol
read-out compani expect patient smart trial new
partnership compani may sign expect addit partnership spring
nipt test oncolog test organ transplant perhap anoth segment
present contempl think hit model time either
next sever year final believ revenu estim
oncolog remain conserv expect materi ramp
time-fram anniversari year test launch initi signatera liquid
biopsi commerci test launch may includ one test lung ovarian
breast colon bladder cancer expect launch sometim get
better sens reimburs pathway oncolog test
rais pt reiter buy rate rais pt
street-high use price/sal multipl
revenu estim discount back two year discount rate
rais pt lh reiter buy rate rais pt labcorp
use multipl adj ep
estim ep estim present model think
lh like lose volum revenu longer
exclus nation lab provid howev believ lh mitig
loss compani like gain access aet exclus
end open begin januari said
revenu ep estim incorpor like benefit
acquisit expect like play come year
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin juli et
date time product juli et
pt use multipl adj ep estim note revenu ep estim
includ expect addit revenu volum gain relat contract begin januari
pt use premium multipl adj ep estim
laboratori corpor america hold lh
price target appli multipl adj ep estim
price target use price/sal multipl revenu estim discount back two year
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
diagnost tool
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
panorama asp compress erod margin gross margin drop sequenti expect
margin continu erod result reduct in-network price commerci payor come on-line
expand includ averag risk patient expect mitig revenu impact asp compress drive
busi profit account though busi may suffer increas test volum outpac asp
relianc lab partner move away lab partner priorit direct sale continu sell
number refer lab partner includ arup clarient sonic unclear durabl compani lab partnership may
particularli sinc lost lab partner past certain lab choos promot anoth nipt decid offer
nipt includ recent quest
fda oversight ldt test lab-develop test ivd fda take posit author
regul test medic devic fdc act gener chosen enforc author mandat certain
ltd seek fda clearanc howev fda look regul ldt use risk-bas approach begin deem
highest-risk devic follow lower risk devic believ panorama would treat moderate-risk high-risk
among highest-risk devic fda indic high-and moderate-risk ltd market
guidelin final remain market fda review submiss expect requir
remov product market regul fda ltd remain subject uncertainti controversi
constel addit talk fda receiv clearanc constel us fda indic
constel platform may appropri review de novo classif allow market
distribut constel us convers on-going fda requir obtain regulatori clearanc
market constel softwar diagnost purpos abl secur fda clearanc compli
on-going fda regulatori requir would unabl commerci constel compani cloud-bas distribut
competit compet directli compani offer nipt carrier screen test ob/gyn mfm
market labcorp roch counsyl mani compani larger abl
leverag economi scale win busi offer multipl test servic women health one requisit form
observ research doctor often switch test brand may make market share gain difficult
strong competit oncolog uncertain time oncolog launch develop liquid biopsi test oncolog
manag size opportun billion initi sampl collect activ lung ovarian
cancer collect dozen collabor includ vanderbilt stanford columbia cancer research uk
other also initi collect effort breast cancer plan announc collabor later year
alon pursu blood-bas test oncolog market leader today substanti base revenu data
counsyl trovagen pathway genom mdx name hand
ethic legal social concern relat genet inform could reduc demand genet test test provid
dna test servic like conduct use panorama expect conduct oncolog may rais ethic legal
social issu regard privaci appropri use result inform government author could social
purpos limit regul use genom inform genom test prohibit test genet predisposit certain
condit particularli known cure similarli concern may lead patient refus use genet test even
permiss ethic social concern may also complic abil protect patent technolog
import medicaid nipt approxim birth unit state state medicaid program recipi
end recogn medicaid provid state state requir compani oper lab
state becom recogn medicaid provid typic medicaid rate price medicar commonli lowest payor
term dollar
diagnost tool
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
canaccord genuiti one affili compani market maker liquid provid secur
laboratori corpor america hold relat deriv
canaccord genuiti one affili compani intend seek expect receiv compens invest bank
servic laboratori corpor america hold next three month
rate histori
laboratori corpor america hold rate histori
diagnost tool
rate histori
rate histori
line articl mifid ii deleg regul disclos price perform preced five year whole period
financi instrument offer invest servic provid less five year pleas note price histori
refer actual past perform past perform reliabl indic futur price and/or perform
